Journal Mobile Options
Table of Contents
Vol. 81, No. 3-4, 2011
Issue release date: December 2011
Oncology 2011;81:143–150
(DOI:10.1159/000330817)

Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials

Yang S.-H. · Kuo Y.-H. · Tien Y.-W. · Hsu C. · Hsu C.-H. · Kuo S.-H. · Cheng A.-L.
Departments of aOncology, bSurgery and cInternal Medicine, National Taiwan University Hospital and College of Medicine, and dCancer Research Center, National Taiwan University College of Medicine, Taipei, and eDepartment of Oncology, National Taiwan University Hospital, Yun-Lin Branch, Yunlin, Taiwan, ROC

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Advanced pancreatic cancer, even when treated, is highly lethal. The best choice of gemcitabine-based therapy and the prognostic factors affecting the success of treatment remain uncertain. Methods: We identified 159 of 1,475 patients with pancreatic cancer diagnosed in our institution and receiving gemcitabine-based chemotherapy between January 1995 and June 2007. Univariate and multivariate analyses were used to evaluate the prognostic significance of various clinical parameters for overall survival (OS). Results: The median survival after gemcitabine-based therapy was 5.4 months; 89.9% (n = 143) had ductal adenocarcinoma, 55.3% (n = 88) with stage IV. Gemcitabine alone was given to 60 (38%) patients, and gemcitabine with high-dose infusional fluorouracil (5-FU) with (n = 25) or without (n = 39) oxaliplatin was given to 64 (40%) patients. All regimens correlated with OS (p = 0.042) but not with the response rate (RR; p = 0.3). The overall RR was 11.1%, and all responders had a good performance status (PS). The RRs to gemcitabine with infusional 5-FU, and gemcitabine with oxaliplatin and infusional 5-FU were 5.3 and 20.8%, respectively. In a multivariate analysis, old age, advanced stage, poor PS and no enrollment in clinical trials were associated with inferior survival. Conclusions: The outcome for patients who did not participate in clinical trials, regardless of gemcitabine-based treatment, is still bleak.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Fatima J, Schnelldorfer T, Barton J, et al: Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg 2010;145:167–172.
  2. Garcea G, Dennison AR, Ong SL, et al: Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007;33:892–897.
  3. Riediger H, Keck T, Wellner U, et al: The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13:1337–1344.
  4. Morganti AG, Massaccesi M, La Torre G, et al: A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010;17:194–205.
  5. Ishii H, Furuse J, Boku N, et al, JCOG Gastrointestinal Oncology Study Group: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol 2010;40:573–579.
  6. Merl MY, Abdelghany O, Li J, Saif MW: First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the ‘2010 ASCO Annual Meeting’, Chicago, Ill., USA. JOP 2010;11:317–320.

    External Resources

  7. Moore MJ, Goldstein D, Hamm J, et al Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–1966.
  8. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605–3610.
  9. Kindler HL, Niedzwiecki D, Hollis D, et al: gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617–3622.
  10. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.
  11. Bayraktar S, Bayraktar UD, Rocha-Lima CM: Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 2010;16:673–682.
  12. Kalser MH, Barkin J, MacIntyre JM: Pancreatic cancer: assessment of prognosis by clinical presentation. Cancer 1985;56:397–402.
  13. Chu CK, Sarmiento JM, Park J, et al: Differences in presentation and perioperative outcome after pancreaticoduodenectomy for cancer and benign pancreatitis. Am Surg 2010;76:606–613.

    External Resources

  14. Boeck S, Hinke A, Wilkowski R, Heinemann V: Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007;13:224–227.
  15. Sultana A, Smith CT, Cunningham D, et al: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25:2607–2615.
  16. Oztop I, Yilmaz U, Yavuzsen T, et al: Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas. Chemotherapy 2004;50:127–132.
  17. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509–3516.
  18. Ch’ang HJ, Huang CL, Wang HP, et al: Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-hour infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer. Cancer Chemother Pharmacol 2009;64:1173–1179.
  19. Reni M, Cordio S, Milandri C, et al: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005;6:369–376.
  20. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. N Engl J Med 2011;364:1817–1825.
  21. Venook AP, Egorin MJ, Rosner GL, et al: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000;18:2780–2787.
  22. Wynder EL: An epidemiological evaluation of the causes of cancer of the pancreas. Cancer Res 1975;35:2228–2233.
  23. Koeppler H, Duru M, Grundheber M, et al: Palliative treatment of advanced pancreatic carcinoma in community-based oncology group practices. J Support Oncol 2004;2:159–163.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50